EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated

Pierre Marquet, Dany Anglicheau, Antoine Humeau, Sofian Adrouche, Lakhdar Saada, Julie Bisiaux, Sara Guillemin, Audrey Lardy-Cléaud, Lionel Rostaing

Transplant International · 2024

DOI: 10.3389/ti.2024.13495 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transplant International, 2024. Verfasst von Pierre Marquet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation, Immunosuppressive Agents, Kidney Failure, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sandoz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

All the factors potentially influencing tacrolimus dose requirement and combinations thereof have never been thoroughly investigated, precluding accurate prediction of tacrolimus starting dose. This prospective, non-interventional, multicenter study in de novo adult kidney transplant recipients over the first year after transplantation aimed to investigate the factors influencing tacrolimus dose-standardized trough blood concentration (C 0 /D) over the first week post-transplant (D4-D7, primary objective), D8-M3 and M3-M12 (secondary objectives). Statistical analysis employed mixed linear models with repeated measures. Eighteen sites enrolled 440 patients and followed them up for 9.5 ± 4.1 months. Age at baseline ( p = 0.0144), end-stage renal disease ( p = 0.0092), CYP3A phenotype ( p < 0.0001), dyslipidemia at baseline ( p = 0.0031), hematocrit ( p = 0.0026), total bilirubin ( p = 0.0261) and plasma creatinine ( p = 0.0484) independently increased with log(C 0 /D) over D4-D7, explaining together 72.3% of the interindividual variability, and representing a robust model to estimate tacrolimus initial dose. Donor age and CYP3A phenotype were also influential over D8-M3 and M3-12, in addition to recipient age. Corticosteroids, diabetes at baseline, and ASAT yielded inconstant results between D8-M3 and M3-M12. We found no ethnicity effect when CYP3A phenotype was accounted for, and no food effect. Intra-individual variability over M3-M12 was moderate, and significantly lower in patients with chronic hepatic disorder ( p = 0.0196) or cancer ( p = 0.0132).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusKidney TransplantationImmunosuppressive AgentsKidney Failure, ChronicCytochrome P-450 CYP3AHumansFemaleMaleMiddle AgedAdultProspective StudiesAgedGraft RejectionCreatinineBilirubinDose-Response Relationship, Drug

Stichwörter der Autor:innen

dietethnicitygenetic polymorphismspharmacokinetic variabilitytacrolimus

Substanzen

TacrolimusImmunosuppressive AgentsCytochrome P-450 CYP3ACreatinineBilirubin

Autor:innen und Institutionen

  • Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France.
  • Pharmacology and Transplantation, UMR1248 Inserm Université de Limoges, Limoges, France.
  • Department of Nephrology and Kidney Transplantation, Necker Hospital, Université Paris Cité, Paris, France.
  • Medical Department, SANDOZ S.A.S, Levallois-Perret, France.
  • Clinical Operations Department, RCTs, Lyon, France.
  • Medical Writing Department, RCTs, Lyon, France.

Förderung

  • Sandoz

Zitieren

APA

Marquet, P., Anglicheau, D., Humeau, A., Adrouche, S., Saada, L., Bisiaux, J., Guillemin, S., Lardy-Cléaud, A., & Rostaing, L. (2024). Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated. Transplant International. https://doi.org/10.3389/ti.2024.13495

Vancouver

Marquet P, Anglicheau D, Humeau A, Adrouche S, Saada L, Bisiaux J, et al. Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated. Transplant International. 2024. doi:10.3389/ti.2024.13495

BibTeX
@article{Marquet2024,
  author = {Marquet, Pierre and Anglicheau, Dany and Humeau, Antoine and Adrouche, Sofian and Saada, Lakhdar and Bisiaux, Julie and Guillemin, Sara and Lardy-Cléaud, Audrey and Rostaing, Lionel},
  title = {Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated},
  journal = {Transplant International},
  year = {2024},
  doi = {10.3389/ti.2024.13495}
}
Kostenlos starten →